EWM
AZN icon

Evolution Wealth Management’s AstraZeneca AZN Stock Holding History

Evolution Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.5K Buy
29
+9
+45% +$1.69K ﹤0.01% 686
2026
Q1 		$3.94K Hold
20
– – ﹤0.01% 656
2025
Q4 		$3.68K Buy
+20
New +$3.51K ﹤0.01% 582

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Evolution Wealth Management's AZN Position: Q2 2026 in Review

Evolution Wealth Management increased its AstraZeneca (AZN) stake by 45% in Q2 2026, buying an estimated $1.69K and bringing the position to 29 shares worth $5.5K. The position accounts for ﹤0.01% of the portfolio, ranked #686.

Evolution Wealth Management first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Evolution Wealth Management held 29 shares of AstraZeneca worth $5.5K as of Q2 2026.
  • Evolution Wealth Management bought 9 AstraZeneca shares in Q2 2026, an estimated $1.69K.
  • AstraZeneca made up ﹤0.01% of Evolution Wealth Management's portfolio in Q2 2026, its #686 holding.
  • Evolution Wealth Management first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Evolution Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.